Sino Biopharmaceutical (FRA:SMZ1) Total Current Assets : €3,230 Mil (As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Sino Biopharmaceutical's total current assets for the quarter that ended in Jun. 2024 was €3,230 Mil.

Sino Biopharmaceutical Total Current Assets Historical Data

The historical data trend for Sino Biopharmaceutical's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Total Current Assets Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

3,196.86

2,865.27

3,265.71

3,511.71

3,057.29

Sino Biopharmaceutical Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Current Assets	Get a 7-Day Free Trial															3,560.32	3,511.71	3,476.98	3,057.29	3,229.80

Sino Biopharmaceutical Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Sino Biopharmaceutical's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1813.166	+	796.074	+	256.017	+	192.034
	=	3,057

Sino Biopharmaceutical's Total Current Assets for the quarter that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1687.666	+	1306.86	+	235.275	+	0
	=	3,230

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Sino Biopharmaceutical (FRA:SMZ1) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Sino Biopharmaceutical's Liquidation Value for the quarter that ended in Jun. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1687.666	-	3147.854	+	0.75 * 923.985	+	0.5 * 235.275
=	-650

Sino Biopharmaceutical Total Current Assets Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA 01177:Hong Kong

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Sino Biopharmaceutical Headlines

No Headlines